163 related articles for article (PubMed ID: 20846757)
1. [Achromobacter xylosoxidans colonisation in bronchiectasis].
Gázquez G
Enferm Infecc Microbiol Clin; 2010 Dec; 28(10):758-9; author reply 759. PubMed ID: 20846757
[No Abstract] [Full Text] [Related]
2. Investigation of hospital-acquired infections due to Achromobacter xylosoxidans in a tertiary care hospital in India.
Kumar A; Ray P; Kanwar M; Sethi S; Narang A
J Hosp Infect; 2006 Feb; 62(2):248-50. PubMed ID: 16289456
[No Abstract] [Full Text] [Related]
3. Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance.
De Baets F; Schelstraete P; Van Daele S; Haerynck F; Vaneechoutte M
J Cyst Fibros; 2007 Jan; 6(1):75-8. PubMed ID: 16793350
[TBL] [Abstract][Full Text] [Related]
4. Achromobacter xylosoxidans mesh related infection: a case of delayed diagnosis and management.
Gupta V; Nirkhiwale S; Gupta P; Phatak S
J Infect; 2012 Mar; 64(3):e1-5. PubMed ID: 21959012
[TBL] [Abstract][Full Text] [Related]
5. Multiple drug-resistant Alcaligenes xylosoxidans keratitis in a sanitation worker.
Kiernan DF; Chin EK; Sclafani LA; Saidel MA
Eye Contact Lens; 2009 Jul; 35(4):212-4. PubMed ID: 19516143
[TBL] [Abstract][Full Text] [Related]
6. Achromobacter xylosoxidans meningitis in an immunosuppressed patient.
Bellissimo F; Pinzone MR; Tosto S; Nunnari G; Cacopardo B
QJM; 2014 Jan; 107(1):65-6. PubMed ID: 23970185
[No Abstract] [Full Text] [Related]
7. [Achromobacter xylosoxidans colonization in bronchiectasis].
Sancho-Chust JN; Agudo P; Camarasa A; Chiner E
Enferm Infecc Microbiol Clin; 2010 Mar; 28(3):203-4. PubMed ID: 19446928
[No Abstract] [Full Text] [Related]
8. Complicated intra-abdominal infection caused by extended drug-resistant Achromobacter xylosoxidans.
Teng SO; Ou TY; Hsieh YC; Lee WC; Lin YC; Lee WS
J Microbiol Immunol Infect; 2009 Apr; 42(2):176-80. PubMed ID: 19597652
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of Achromobacter xylosoxidans bacteremia in northern Taiwan.
Shie SS; Huang CT; Leu HS
J Microbiol Immunol Infect; 2005 Aug; 38(4):277-82. PubMed ID: 16118676
[TBL] [Abstract][Full Text] [Related]
10. Bilateral simultaneous Achromobacter xylosoxidans keratitis following penetrating keratoplasty.
Srinivasan S; McAllum P; Poutanen SM; Slomovic AR
J Cataract Refract Surg; 2006 Dec; 32(12):2149-52. PubMed ID: 17138001
[TBL] [Abstract][Full Text] [Related]
11. Epidemiology and resistance of Achromobacter xylosoxidans from cystic fibrosis patients in Dijon, Burgundy: first French data.
Amoureux L; Bador J; Siebor E; Taillefumier N; Fanton A; Neuwirth C
J Cyst Fibros; 2013 Mar; 12(2):170-6. PubMed ID: 22944724
[TBL] [Abstract][Full Text] [Related]
12. Fluorescence in situ hybridization for rapid identification of Achromobacter xylosoxidans and Alcaligenes faecalis recovered from cystic fibrosis patients.
Wellinghausen N; Wirths B; Poppert S
J Clin Microbiol; 2006 Sep; 44(9):3415-7. PubMed ID: 16954289
[TBL] [Abstract][Full Text] [Related]
13. Infection of a total hip prosthesis in a dog caused by Achromobacter(Alcaligenes) xylosoxidans.
Girling SL; Innes JF
J Small Anim Pract; 2006 Dec; 47(12):747-50. PubMed ID: 17201829
[TBL] [Abstract][Full Text] [Related]
14. Innate aminoglycoside resistance of Achromobacter xylosoxidans is due to AxyXY-OprZ, an RND-type multidrug efflux pump.
Bador J; Amoureux L; Blanc E; Neuwirth C
Antimicrob Agents Chemother; 2013 Jan; 57(1):603-5. PubMed ID: 23089757
[TBL] [Abstract][Full Text] [Related]
15. AcGI1, a novel genomic island carrying antibiotic resistance integron In687 in multidrug resistant Achromobacter xylosoxidans in a teaching hospital in Thailand.
Pongchaikul P; Santanirand P; Antonyuk S; Winstanley C; Darby AC
FEMS Microbiol Lett; 2020 Jul; 367(14):. PubMed ID: 32592387
[TBL] [Abstract][Full Text] [Related]
16. Achromobacter xylosoxidans Bacteremia and Cellulitis: A Report of a Case.
Dai J; Huen AO; Kestenbaum LA; Sarezky MD; Coughlin CC; Yan AC
Pediatr Dermatol; 2015; 32(4):e186-7. PubMed ID: 25973735
[TBL] [Abstract][Full Text] [Related]
17. Distribution of the species of Achromobacter in a French Cystic Fibrosis Centre and multilocus sequence typing analysis reveal the predominance of A. xylosoxidans and clonal relationships between some clinical and environmental isolates.
Amoureux L; Bador J; Bounoua Zouak F; Chapuis A; de Curraize C; Neuwirth C
J Cyst Fibros; 2016 Jul; 15(4):486-94. PubMed ID: 26778615
[TBL] [Abstract][Full Text] [Related]
18. In vitro synergistic activity of combined piperacillin and tobramycin against clinical strains of Achromobacter xylosoxidans.
Duez JM; Hadjait-Savioz M; Siebor E; Astruc K; Bador J; Péchinot A; Sixt N; Huet F; Neuwirth C
J Chemother; 2010 Apr; 22(2):139-41. PubMed ID: 20435577
[No Abstract] [Full Text] [Related]
19. Study of 109 Achromobacter spp. isolates from 9 French CF centres reveals the circulation of a multiresistant clone of A. xylosoxidans belonging to ST 137.
Amoureux L; Sauge J; Sarret B; Lhoumeau M; Bajard A; Tetu J; Bador J; Neuwirth C;
J Cyst Fibros; 2019 Nov; 18(6):804-807. PubMed ID: 31104975
[TBL] [Abstract][Full Text] [Related]
20. First description of an RND-type multidrug efflux pump in Achromobacter xylosoxidans, AxyABM.
Bador J; Amoureux L; Duez JM; Drabowicz A; Siebor E; Llanes C; Neuwirth C
Antimicrob Agents Chemother; 2011 Oct; 55(10):4912-4. PubMed ID: 21807978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
